What is PathAI?
Headquartered in Boston, Massachusetts, PathAI is at the forefront of applying artificial intelligence to pathology. The company collaborates with leading life sciences organizations and researchers to enhance the accuracy of disease diagnosis and treatment efficacy, particularly in areas like cancer. PathAI's platform provides crucial improvements for diagnostic processes, enabling more precise and effective patient care. The company's work is instrumental in the broader push towards precision medicine, leveraging advanced technology to unlock deeper insights from pathological data.
How much funding has PathAI raised?
PathAI has raised a total of $180.2M across 3 funding rounds:
Other Financing Round
$4.2M
Series A
$11M
Series C
$165M
Other Financing Round (2016): $4.2M with participation from Pillar VC, Refactor Capital, 8VC, and Fairhaven Capital
Series A (2017): $11M led by KdT Ventures, General Catalyst, Danhua Capital, 8VC, Refactor Capital, and Pillar VC
Series C (2021): $165M supported by General Atlantic, Polaris Partners, KdT Ventures, Labcorp, 8VC, Adage Technologies, Kaiser Permanente, Tiger Global Management, Biospring Partners, Merck Global Health Innovation Fund, General Catalyst, Bristol-Myers Squibb, Refactor Capital, and D1 Capital Partners
Key Investors in PathAI
General Atlantic
General Atlantic is a global growth equity firm that provides capital and strategic support to high-growth companies in sectors such as consumer, financial services, healthcare, life sciences, and technology. They partner with founders and management teams to accelerate growth and international expansion.
General Catalyst
General Catalyst is a venture capital firm focused on identifying and supporting transformational business opportunities across multiple sectors and stages, leveraging deep sector expertise and operational experience to accelerate growth and build enduring enterprises.
KdT Ventures
KdT Ventures is a venture capital firm specializing in early-stage frontier science investing, focusing on transformative technologies in medicine, chemicals, and materials, often providing the first institutional check into companies.
What's next for PathAI?
The substantial enterprise-level funding, including the recent strategic investment, positions PathAI for accelerated expansion and innovation. This capital infusion is expected to fuel further development of its AI-driven pathology solutions, potentially broadening its service offerings and market reach. PathAI is likely to invest in enhancing its platform's capabilities, expanding its research collaborations, and scaling its operations to meet the growing demand for advanced diagnostic tools in the life sciences and healthcare industries. The company's trajectory suggests a strong focus on solidifying its leadership in AI-powered pathology and contributing significantly to the future of precision medicine.
See full PathAI company page
